You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameVilazodone
Accession NumberDB06684
TypeSmall Molecule
GroupsApproved
DescriptionVilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors. It has been shown to be equally efficacious as other antidepressants with similar gastrointestinal side effects and possibly with reduced sexual side effects and weight gain. Vilazodone is an antidepressant agent that can used as an alternative for patients who cannot tolerate therapy with other antidepressant classes such as selective serotonin reuptake inhibitors or serotonin norepinephrine reuptake inhibitors. Treatment should be titrated towards the target dose, which is 40mg per day.
Structure
Thumb
Synonyms
Vilazodona
Vilazodonum
External Identifiers
  • EMD-68843
  • SB 659746A
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Viibrydtablet10 mg/1oralAvera Mc Kennan Hospital2015-03-03Not applicableUs
ViibrydkitoralForest Laboratories, Inc.2011-04-29Not applicableUs
Viibrydtablet40 mg/1oralForest Laboratories, Inc.2011-04-29Not applicableUs
Viibrydtablet10 mgoralForest Laboratories Canada IncNot applicableNot applicableCanada
ViibrydkitoralForest Laboratories, Inc.2011-04-29Not applicableUs
Viibrydtablet40 mg/1oralCardinal Health2011-04-29Not applicableUs
Viibrydtablet20 mgoralForest Laboratories Canada IncNot applicableNot applicableCanada
Viibrydtablet10 mg/1oralForest Laboratories, Inc.2011-04-29Not applicableUs
Viibrydtablet40 mg/1oralAvera Mc Kennan Hospital2015-03-10Not applicableUs
Viibrydtablet40 mgoralForest Laboratories Canada IncNot applicableNot applicableCanada
Viibrydtablet20 mg/1oralForest Laboratories, Inc.2011-04-29Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
ViibrydForest Laboratories Canada Inc
Salts
Name/CASStructureProperties
Vilazodone hydrochloride
163521-08-2
Thumb
  • InChI Key: RPZBRGFNBNQSOP-UHFFFAOYSA-N
  • Monoisotopic Mass: 477.193152872
  • Average Mass: 477.986
DBSALT000187
Categories
UNIIS239O2OOV3
CAS number163521-12-8
WeightAverage: 441.5249
Monoisotopic: 441.216475133
Chemical FormulaC26H27N5O2
InChI KeyInChIKey=SGEGOXDYSFKCPT-UHFFFAOYSA-N
InChI
InChI=1S/C26H27N5O2/c27-16-18-4-6-23-22(13-18)19(17-29-23)3-1-2-8-30-9-11-31(12-10-30)21-5-7-24-20(14-21)15-25(33-24)26(28)32/h4-7,13-15,17,29H,1-3,8-12H2,(H2,28,32)
IUPAC Name
5-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-1-benzofuran-2-carboxamide
SMILES
NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentN-arylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Indole or derivatives
  • Indole
  • Benzofuran
  • Dialkylarylamine
  • Benzonitrile
  • Aralkylamine
  • N-alkylpiperazine
  • Benzenoid
  • Substituted pyrrole
  • Heteroaromatic compound
  • Pyrrole
  • Furan
  • Tertiary aliphatic amine
  • Tertiary amine
  • Primary carboxylic acid amide
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Nitrile
  • Carbonitrile
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationVilazodone is approved for treatment of acute episodes of major depression. Labeling of vilazodone describes an increased risk of suicidal thoughts in children, adolescents and young adults. The use of vilazodone in pediatrics is not indicated. Its use with monoamine oxidase inhibitors (MAOI) is contraindicated due to increased risk of serotonin syndome. Once the MAOI is discontinued, a 14-day washout period must pass before starting vilazodone.
PharmacodynamicsVilazodone increases serotonin levels in the brain by inhibiting the reuptake of serotonin while acting as a partial agonist on serotonin-1A receptors. It has therefore been coined by scientists as a selective partial agonist and reuptake inhibitor (SPARI). Because of its partial agonist activity for serotonin-1A, vilazodone helps to reduce anxiety.
Mechanism of actionSince serotonin is believed to be one of the three main neurotransmitters that is low or imbalanced in patients with depression- pathways seeking to increase serotonin levels are targeted by pharmaceutical companies. As a selective serotonin reuptake inhibitor, vilazodone prevents serotonin from re-entering cell bodies. Hence, they will remain longer in the synapse. Vilazodone also has an inherent selectivity for serotonin-1A receptors, acting as a partial agonist which stimulates the production of serotonin. The end result is increased serotonin in the synaptic cleft, allowing serotonin to resume its action on nearby cells. The mechanism of the antidepressant effect of vilazodone is not fully understood, but is thought to be related to its enhancement of serotonergic activity in the CNS through selective inhibition of serotonin reuptake.
Related Articles
AbsorptionVilazodone's absorption is improved when taken with food to 72%.
Volume of distributionNot Available
Protein binding96-99% protein bound
Metabolism

Major: CYP3A4. Minor: CYP2C19 and CYP2D6

Route of elimination1% recovered in urine. 2% unchanged in feces.
Half life25.4h
Clearance

21.1L/h

ToxicityVomiting, serotonin syndrome.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9959
Blood Brain Barrier+0.9694
Caco-2 permeable-0.6764
P-glycoprotein substrateSubstrate0.6362
P-glycoprotein inhibitor IInhibitor0.581
P-glycoprotein inhibitor IIInhibitor0.9022
Renal organic cation transporterNon-inhibitor0.527
CYP450 2C9 substrateNon-substrate0.9138
CYP450 2D6 substrateNon-substrate0.5431
CYP450 3A4 substrateSubstrate0.5983
CYP450 1A2 substrateNon-inhibitor0.5637
CYP450 2C9 inhibitorInhibitor0.5397
CYP450 2D6 inhibitorNon-inhibitor0.7021
CYP450 2C19 inhibitorInhibitor0.6998
CYP450 3A4 inhibitorNon-inhibitor0.6258
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8731
Ames testNon AMES toxic0.6088
CarcinogenicityNon-carcinogens0.9181
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6208 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8967
hERG inhibition (predictor II)Inhibitor0.87
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Kitoral
Kit; tabletoral
Tabletoral10 mg
Tabletoral10 mg/1
Tabletoral20 mg
Tabletoral20 mg/1
Tabletoral40 mg
Tabletoral40 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5532241 No1999-09-292019-09-29Us
US7834020 No2002-06-052022-06-05Us
US8193195 No2002-06-052022-06-05Us
US8236804 No2002-06-052022-06-05Us
US8673921 No2002-06-052022-06-05Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityAqueous solubility is 0.32 mg/mLNot Available
pKa7.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.123 mg/mLALOGPS
logP4.21ALOGPS
logP3.72ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)14.19ChemAxon
pKa (Strongest Basic)8.6ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area102.29 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity129.71 m3·mol-1ChemAxon
Polarizability50.02 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Khan A, Cutler AJ, Kajdasz DK, Gallipoli S, Athanasiou M, Robinson DS, Whalen H, Reed CR: A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry. 2011 Apr;72(4):441-7. doi: 10.4088/JCP.10m06596. [PubMed:21527122 ]
  2. Traynor K: Vilazodone approved for major depression. Am J Health Syst Pharm. 2011 Mar 1;68(5):366. doi: 10.2146/news110009. [PubMed:21330672 ]
  3. Howland RH: Vilazodone: another novel atypical antidepressant drug. J Psychosoc Nurs Ment Health Serv. 2011 Mar;49(3):19-22. doi: 10.3928/02793695-20110203-98. Epub 2011 Feb 16. [PubMed:21323263 ]
  4. Dawson LA, Watson JM: Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci Ther. 2009 Summer;15(2):107-17. [PubMed:19499624 ]
  5. de Paulis T: Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression. IDrugs. 2007 Mar;10(3):193-201. [PubMed:17351874 ]
  6. Page ME, Cryan JF, Sullivan A, Dalvi A, Saucy B, Manning DR, Lucki I: Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist. J Pharmacol Exp Ther. 2002 Sep;302(3):1220-7. [PubMed:12183683 ]
  7. Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU: A review of current evidence for vilazodone in major depressive disorder. Int J Psychiatry Clin Pract. 2013 Aug;17(3):160-9. doi: 10.3109/13651501.2013.794245. Epub 2013 May 29. [PubMed:23578403 ]
  8. Dopheide JA: Vilazodone's comparative merits yet to be demonstrated. Am J Health Syst Pharm. 2012 Sep 15;69(18):1549. doi: 10.2146/ajhp110570. [PubMed:22935936 ]
External Links
ATC CodesN06AX24
AHFS Codes
  • 28:16.04.24
PDB EntriesNot Available
FDA labelDownload (164 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Vilazodone.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Vilazodone.
AbirateroneThe metabolism of Vilazodone can be decreased when combined with Abiraterone.
AcarboseVilazodone may increase the hypoglycemic activities of Acarbose.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Vilazodone.
AcenocoumarolVilazodone may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Vilazodone.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Vilazodone.
AcetophenazineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Acetophenazine.
Acetylsalicylic acidVilazodone may increase the antiplatelet activities of Acetylsalicylic acid.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Vilazodone.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Vilazodone.
AlbiglutideVilazodone may increase the hypoglycemic activities of Albiglutide.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Vilazodone.
AlfentanilAlfentanil may increase the serotonergic activities of Vilazodone.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Vilazodone.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Vilazodone.
AlogliptinVilazodone may increase the hypoglycemic activities of Alogliptin.
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Vilazodone.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Vilazodone.
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Vilazodone.
AmiodaroneThe metabolism of Vilazodone can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Vilazodone.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Vilazodone.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Vilazodone.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Vilazodone.
AmoxapineVilazodone may increase the serotonergic activities of Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Vilazodone.
AprepitantThe serum concentration of Vilazodone can be increased when it is combined with Aprepitant.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Vilazodone.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Vilazodone.
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Vilazodone.
ArtemetherThe metabolism of Vilazodone can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Vilazodone.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Vilazodone.
AtazanavirThe serum concentration of Vilazodone can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Vilazodone.
AtomoxetineThe serum concentration of Vilazodone can be increased when it is combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Vilazodone.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Vilazodone.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Vilazodone.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Vilazodone.
BefunololThe serum concentration of Befunolol can be increased when it is combined with Vilazodone.
BendroflumethiazideVilazodone may increase the hyponatremic activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the serotonergic activities of Vilazodone.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Vilazodone.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Vilazodone.
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Vilazodone.
BetaxololThe metabolism of Vilazodone can be decreased when combined with Betaxolol.
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Vilazodone.
BexaroteneThe serum concentration of Vilazodone can be decreased when it is combined with Bexarotene.
BezitramideBezitramide may increase the serotonergic activities of Vilazodone.
BifeprunoxThe risk or severity of adverse effects can be increased when Vilazodone is combined with Bifeprunox.
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Vilazodone.
BoceprevirThe serum concentration of Vilazodone can be increased when it is combined with Boceprevir.
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Vilazodone.
BortezomibThe serum concentration of Vilazodone can be increased when it is combined with Bortezomib.
BosentanThe serum concentration of Vilazodone can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Vilazodone.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Vilazodone.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Vilazodone.
BromocriptineVilazodone may increase the hypoglycemic activities of Bromocriptine.
BromocriptineBromocriptine may increase the vasoconstricting activities of Vilazodone.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Vilazodone.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Vilazodone.
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Vilazodone.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Vilazodone.
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Vilazodone.
BuprenorphineBuprenorphine may increase the serotonergic activities of Vilazodone.
BupropionThe metabolism of Vilazodone can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Vilazodone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Vilazodone.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Vilazodone.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Vilazodone.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Vilazodone.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Vilazodone.
ButorphanolButorphanol may increase the serotonergic activities of Vilazodone.
CabergolineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Cabergoline.
CabergolineCabergoline may increase the vasoconstricting activities of Vilazodone.
CanagliflozinVilazodone may increase the hypoglycemic activities of Canagliflozin.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Vilazodone.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Vilazodone.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Vilazodone.
CarfentanilCarfentanil may increase the serotonergic activities of Vilazodone.
CariprazineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Vilazodone.
CaroxazoneCaroxazone may increase the serotonergic activities of Vilazodone.
CarteololThe serum concentration of Carteolol can be increased when it is combined with Vilazodone.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Vilazodone.
CelecoxibThe metabolism of Vilazodone can be decreased when combined with Celecoxib.
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Vilazodone.
CeritinibThe serum concentration of Vilazodone can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Vilazodone.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Vilazodone.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Vilazodone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Vilazodone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Vilazodone.
ChloroquineThe metabolism of Vilazodone can be decreased when combined with Chloroquine.
ChlorothiazideVilazodone may increase the hyponatremic activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Vilazodone.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Vilazodone.
ChlorpropamideVilazodone may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Vilazodone.
ChlorthalidoneVilazodone may increase the hyponatremic activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Vilazodone.
CholecalciferolThe metabolism of Vilazodone can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Vilazodone can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Vilazodone can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Vilazodone.
CitalopramVilazodone may increase the serotonergic activities of Citalopram.
CitalopramThe metabolism of Vilazodone can be decreased when combined with Citalopram.
ClarithromycinThe serum concentration of Vilazodone can be increased when it is combined with Clarithromycin.
ClemastineThe serum concentration of Vilazodone can be increased when it is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Vilazodone.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Vilazodone.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Vilazodone.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Vilazodone.
ClomipramineVilazodone may increase the serotonergic activities of Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Vilazodone.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Vilazodone.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Vilazodone.
ClotrimazoleThe serum concentration of Vilazodone can be increased when it is combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Vilazodone.
CobicistatThe serum concentration of Vilazodone can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Vilazodone.
CodeineCodeine may increase the serotonergic activities of Vilazodone.
ConivaptanThe serum concentration of Vilazodone can be increased when it is combined with Conivaptan.
CrizotinibThe serum concentration of Vilazodone can be increased when it is combined with Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Vilazodone.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Vilazodone.
CyclosporineThe serum concentration of Vilazodone can be increased when it is combined with Cyclosporine.
CyproheptadineThe therapeutic efficacy of Vilazodone can be decreased when used in combination with Cyproheptadine.
DabrafenibThe serum concentration of Vilazodone can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Vilazodone.
DapagliflozinVilazodone may increase the hypoglycemic activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Vilazodone.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Vilazodone.
DapoxetineVilazodone may increase the serotonergic activities of Dapoxetine.
DarifenacinThe metabolism of Vilazodone can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Vilazodone can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Vilazodone can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Vilazodone can be decreased when it is combined with Deferasirox.
DelavirdineThe serum concentration of Vilazodone can be increased when it is combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Vilazodone.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Vilazodone.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Vilazodone.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Vilazodone.
DesmopressinThe risk or severity of adverse effects can be increased when Vilazodone is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Vilazodone.
DexamethasoneThe serum concentration of Vilazodone can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vilazodone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Vilazodone.
DextromethorphanVilazodone may increase the serotonergic activities of Dextromethorphan.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Vilazodone.
DextromoramideDextromoramide may increase the serotonergic activities of Vilazodone.
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Vilazodone.
DezocineDezocine may increase the serotonergic activities of Vilazodone.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Vilazodone.
DicoumarolVilazodone may increase the anticoagulant activities of Dicoumarol.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Vilazodone.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Vilazodone.
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Vilazodone.
DihydroergotamineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Dihydroergotamine.
DihydroergotamineDihydroergotamine may increase the vasoconstricting activities of Vilazodone.
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Vilazodone.
DihydromorphineDihydromorphine may increase the serotonergic activities of Vilazodone.
DiltiazemThe serum concentration of Vilazodone can be increased when it is combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Vilazodone.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Vilazodone.
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Vilazodone.
DisopyramideVilazodone may increase the hypoglycemic activities of Disopyramide.
DolasetronDolasetron may increase the serotonergic activities of Vilazodone.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Vilazodone.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Vilazodone.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Vilazodone.
DoxycyclineThe serum concentration of Vilazodone can be increased when it is combined with Doxycycline.
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Vilazodone.
DPDPEDPDPE may increase the serotonergic activities of Vilazodone.
DronedaroneThe serum concentration of Vilazodone can be increased when it is combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Vilazodone.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Vilazodone.
DroxidopaVilazodone may increase the hypertensive activities of Droxidopa.
DulaglutideVilazodone may increase the hypoglycemic activities of Dulaglutide.
DuloxetineThe metabolism of Vilazodone can be decreased when combined with Duloxetine.
DuloxetineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Vilazodone.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Vilazodone.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Vilazodone.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Vilazodone.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Vilazodone.
EliglustatThe metabolism of Vilazodone can be decreased when combined with Eliglustat.
EmpagliflozinVilazodone may increase the hypoglycemic activities of Empagliflozin.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Vilazodone.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Vilazodone.
EnzalutamideThe serum concentration of Vilazodone can be decreased when it is combined with Enzalutamide.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Vilazodone is combined with Ergoloid mesylate.
Ergoloid mesylateErgoloid mesylate may increase the vasoconstricting activities of Vilazodone.
ErgonovineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Ergonovine.
ErgonovineErgonovine may increase the vasoconstricting activities of Vilazodone.
ErgotamineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Ergotamine.
ErgotamineErgotamine may increase the vasoconstricting activities of Vilazodone.
ErythromycinThe serum concentration of Vilazodone can be increased when it is combined with Erythromycin.
EscitalopramEscitalopram may increase the serotonergic activities of Vilazodone.
Eslicarbazepine acetateThe serum concentration of Vilazodone can be decreased when it is combined with Eslicarbazepine acetate.
EsmololThe serum concentration of Esmolol can be increased when it is combined with Vilazodone.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Vilazodone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Vilazodone.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Vilazodone.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vilazodone.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Vilazodone.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Vilazodone.
Ethyl biscoumacetateVilazodone may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Vilazodone.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Vilazodone.
EthylmorphineEthylmorphine may increase the serotonergic activities of Vilazodone.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Vilazodone.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Vilazodone.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Vilazodone.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Vilazodone.
EtoperidoneVilazodone may increase the serotonergic activities of Etoperidone.
EtorphineEtorphine may increase the serotonergic activities of Vilazodone.
EtravirineThe serum concentration of Vilazodone can be decreased when it is combined with Etravirine.
ExenatideVilazodone may increase the hypoglycemic activities of Exenatide.
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Vilazodone.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Vilazodone.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Vilazodone.
FenfluramineFenfluramine may increase the serotonergic activities of Vilazodone.
FentanylFentanyl may increase the serotonergic activities of Vilazodone.
FentanylThe risk or severity of adverse effects can be increased when Vilazodone is combined with Fentanyl.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Vilazodone.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Vilazodone.
FluconazoleThe serum concentration of Vilazodone can be increased when it is combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Vilazodone.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Vilazodone.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Vilazodone.
FluoxetineFluoxetine may increase the serotonergic activities of Vilazodone.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Vilazodone.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Vilazodone.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Vilazodone.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Vilazodone.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Vilazodone.
FluvoxamineThe serum concentration of Vilazodone can be increased when it is combined with Fluvoxamine.
FluvoxamineVilazodone may increase the serotonergic activities of Fluvoxamine.
FosamprenavirThe serum concentration of Vilazodone can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Vilazodone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Vilazodone.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Vilazodone.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Vilazodone.
FurazolidoneFurazolidone may increase the serotonergic activities of Vilazodone.
Fusidic AcidThe serum concentration of Vilazodone can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Vilazodone.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Vilazodone.
GalantamineThe metabolism of Galantamine can be decreased when combined with Vilazodone.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Vilazodone.
GliclazideVilazodone may increase the hypoglycemic activities of Gliclazide.
GlimepirideVilazodone may increase the hypoglycemic activities of Glimepiride.
GlipizideVilazodone may increase the hypoglycemic activities of Glipizide.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Vilazodone.
GlyburideVilazodone may increase the hypoglycemic activities of Glyburide.
GranisetronGranisetron may increase the serotonergic activities of Vilazodone.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Vilazodone.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Vilazodone.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Vilazodone.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Vilazodone.
HeroinHeroin may increase the serotonergic activities of Vilazodone.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Vilazodone.
HydracarbazineHydracarbazine may increase the serotonergic activities of Vilazodone.
HydrochlorothiazideVilazodone may increase the hyponatremic activities of Hydrochlorothiazide.
HydrocodoneHydrocodone may increase the serotonergic activities of Vilazodone.
HydroflumethiazideVilazodone may increase the hyponatremic activities of Hydroflumethiazide.
HydromorphoneHydromorphone may increase the serotonergic activities of Vilazodone.
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Vilazodone.
IdelalisibThe serum concentration of Vilazodone can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Vilazodone.
ImatinibThe serum concentration of Vilazodone can be increased when it is combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Vilazodone.
IndalpineVilazodone may increase the serotonergic activities of Indalpine.
IndapamideVilazodone may increase the hyponatremic activities of Indapamide.
IndenololThe serum concentration of Indenolol can be increased when it is combined with Vilazodone.
IndinavirThe metabolism of Vilazodone can be decreased when combined with Indinavir.
Insulin AspartVilazodone may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirVilazodone may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineVilazodone may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineVilazodone may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanVilazodone may increase the hypoglycemic activities of Insulin Human.
Insulin LisproVilazodone may increase the hypoglycemic activities of Insulin Lispro.
Ioflupane I-123Vilazodone may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IproclozideIproclozide may increase the serotonergic activities of Vilazodone.
IproniazidIproniazid may increase the serotonergic activities of Vilazodone.
IsavuconazoniumThe serum concentration of Vilazodone can be increased when it is combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Vilazodone.
IsocarboxazidThe risk or severity of adverse effects can be increased when Vilazodone is combined with Isocarboxazid.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Vilazodone.
IsoniazidThe metabolism of Vilazodone can be decreased when combined with Isoniazid.
IsradipineThe serum concentration of Vilazodone can be increased when it is combined with Isradipine.
ItraconazoleThe serum concentration of Vilazodone can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Vilazodone can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Vilazodone.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Vilazodone.
KetobemidoneKetobemidone may increase the serotonergic activities of Vilazodone.
KetoconazoleThe metabolism of Vilazodone can be decreased when combined with Ketoconazole.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Vilazodone.
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Vilazodone.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Vilazodone.
LanreotideVilazodone may increase the hypoglycemic activities of Lanreotide.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Vilazodone.
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Vilazodone.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Vilazodone.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Vilazodone.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Vilazodone.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Vilazodone.
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Vilazodone.
LevomilnacipranVilazodone may increase the serotonergic activities of Levomilnacipran.
LevorphanolLevorphanol may increase the serotonergic activities of Vilazodone.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Vilazodone.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Vilazodone.
LinezolidLinezolid may increase the serotonergic activities of Vilazodone.
LinezolidThe risk or severity of adverse effects can be increased when Vilazodone is combined with Linezolid.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Vilazodone.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Vilazodone.
LiraglutideVilazodone may increase the hypoglycemic activities of Liraglutide.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Vilazodone.
LofentanilLofentanil may increase the serotonergic activities of Vilazodone.
LopinavirThe serum concentration of Vilazodone can be increased when it is combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Vilazodone.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Vilazodone.
LorcaserinThe metabolism of Vilazodone can be decreased when combined with Lorcaserin.
LorcaserinThe risk or severity of adverse effects can be increased when Vilazodone is combined with Lorcaserin.
LovastatinThe serum concentration of Vilazodone can be increased when it is combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Vilazodone.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Vilazodone.
Lu AA21004Vilazodone may increase the serotonergic activities of Lu AA21004.
LuliconazoleThe serum concentration of Vilazodone can be increased when it is combined with Luliconazole.
LumefantrineThe metabolism of Vilazodone can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Vilazodone.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Vilazodone.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Vilazodone.
MebanazineMebanazine may increase the serotonergic activities of Vilazodone.
MecaserminVilazodone may increase the hypoglycemic activities of Mecasermin.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Vilazodone.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Vilazodone.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Vilazodone.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Vilazodone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Vilazodone.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Vilazodone.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Vilazodone.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Vilazodone.
MetforminVilazodone may increase the hypoglycemic activities of Metformin.
MethadoneThe metabolism of Methadone can be decreased when combined with Vilazodone.
MethadoneMethadone may increase the serotonergic activities of Vilazodone.
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Vilazodone.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Vilazodone.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Vilazodone.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Vilazodone.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Vilazodone.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Vilazodone.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Vilazodone.
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Vilazodone.
MethyclothiazideVilazodone may increase the hyponatremic activities of Methyclothiazide.
Methylene blueVilazodone may increase the serotonergic activities of Methylene blue.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Vilazodone.
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Vilazodone.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Vilazodone.
MetolazoneVilazodone may increase the hyponatremic activities of Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Vilazodone.
MetoprololThe metabolism of Vilazodone can be decreased when combined with Metoprolol.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Vilazodone.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Vilazodone.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Vilazodone.
MifepristoneThe serum concentration of Vilazodone can be increased when it is combined with Mifepristone.
MifepristoneVilazodone may increase the hypoglycemic activities of Mifepristone.
MiglitolVilazodone may increase the hypoglycemic activities of Miglitol.
MilnacipranMilnacipran may increase the serotonergic activities of Vilazodone.
MinaprineMinaprine may increase the serotonergic activities of Vilazodone.
MirabegronThe metabolism of Vilazodone can be decreased when combined with Mirabegron.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Vilazodone.
MitotaneThe serum concentration of Vilazodone can be decreased when it is combined with Mitotane.
MoclobemideMoclobemide may increase the serotonergic activities of Vilazodone.
MoclobemideThe risk or severity of adverse effects can be increased when Vilazodone is combined with Moclobemide.
ModafinilThe serum concentration of Vilazodone can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Vilazodone.
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Vilazodone.
MorphineMorphine may increase the serotonergic activities of Vilazodone.
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Vilazodone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Vilazodone.
NafcillinThe serum concentration of Vilazodone can be decreased when it is combined with Nafcillin.
NalbuphineNalbuphine may increase the serotonergic activities of Vilazodone.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Vilazodone.
NateglinideVilazodone may increase the hypoglycemic activities of Nateglinide.
NefazodoneThe serum concentration of Vilazodone can be increased when it is combined with Nefazodone.
NefazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Nefazodone.
NelfinavirThe serum concentration of Vilazodone can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Vilazodone can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Vilazodone can be increased when it is combined with Nevirapine.
NialamideNialamide may increase the serotonergic activities of Vilazodone.
NicardipineThe metabolism of Vilazodone can be decreased when combined with Nicardipine.
NilotinibThe serum concentration of Vilazodone can be increased when it is combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Vilazodone.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Vilazodone.
NormethadoneNormethadone may increase the serotonergic activities of Vilazodone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Vilazodone.
OctamoxinOctamoxin may increase the serotonergic activities of Vilazodone.
OctreotideVilazodone may increase the hypoglycemic activities of Octreotide.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Vilazodone.
OlaparibThe serum concentration of Vilazodone can be increased when it is combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Vilazodone.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Vilazodone.
OpiumOpium may increase the serotonergic activities of Vilazodone.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Vilazodone.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Vilazodone.
OsimertinibThe serum concentration of Vilazodone can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Vilazodone.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Vilazodone.
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Vilazodone.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Vilazodone.
OxycodoneOxycodone may increase the serotonergic activities of Vilazodone.
OxymorphoneOxymorphone may increase the serotonergic activities of Vilazodone.
PalbociclibThe serum concentration of Vilazodone can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Vilazodone.
PalonosetronPalonosetron may increase the serotonergic activities of Vilazodone.
PanobinostatThe metabolism of Vilazodone can be decreased when combined with Panobinostat.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Vilazodone.
PargylinePargyline may increase the serotonergic activities of Vilazodone.
ParoxetineParoxetine may increase the serotonergic activities of Vilazodone.
PasireotideVilazodone may increase the hypoglycemic activities of Pasireotide.
Peginterferon alfa-2bThe serum concentration of Vilazodone can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Vilazodone.
PentamidineVilazodone may increase the hypoglycemic activities of Pentamidine.
PentazocinePentazocine may increase the serotonergic activities of Vilazodone.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Vilazodone.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Vilazodone.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Vilazodone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Vilazodone.
PethidinePethidine may increase the serotonergic activities of Vilazodone.
PethidineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Pethidine.
PhenelzinePhenelzine may increase the serotonergic activities of Vilazodone.
PhenelzineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Phenelzine.
PhenindioneVilazodone may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Vilazodone.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Vilazodone.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Vilazodone.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Vilazodone.
PhenprocoumonVilazodone may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Vilazodone.
PimozideThe risk or severity of adverse effects can be increased when Vilazodone is combined with Pimozide.
PindololThe serum concentration of Pindolol can be increased when it is combined with Vilazodone.
PioglitazoneVilazodone may increase the hypoglycemic activities of Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Vilazodone.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Vilazodone.
PirlindolePirlindole may increase the serotonergic activities of Vilazodone.
PivhydrazinePivhydrazine may increase the serotonergic activities of Vilazodone.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Vilazodone.
PolythiazideVilazodone may increase the hyponatremic activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Vilazodone.
PosaconazoleThe serum concentration of Vilazodone can be increased when it is combined with Posaconazole.
PractololThe serum concentration of Practolol can be increased when it is combined with Vilazodone.
PramlintideVilazodone may increase the hypoglycemic activities of Pramlintide.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Vilazodone.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Vilazodone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Vilazodone.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Vilazodone.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Vilazodone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Vilazodone.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Vilazodone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vilazodone.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Vilazodone.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Vilazodone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Vilazodone.
PropericiazineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Vilazodone.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Vilazodone.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Vilazodone.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Vilazodone.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Vilazodone.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Vilazodone.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Vilazodone.
QuinethazoneVilazodone may increase the hyponatremic activities of Quinethazone.
QuinidineThe metabolism of Vilazodone can be decreased when combined with Quinidine.
QuinineVilazodone may increase the hypoglycemic activities of Quinine.
QuinineThe metabolism of Vilazodone can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Vilazodone.
RanolazineThe serum concentration of Vilazodone can be increased when it is combined with Ranolazine.
RasagilineRasagiline may increase the serotonergic activities of Vilazodone.
RasagilineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Rasagiline.
RemifentanilRemifentanil may increase the serotonergic activities of Vilazodone.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Vilazodone.
RepaglinideVilazodone may increase the hypoglycemic activities of Repaglinide.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Vilazodone.
RifabutinThe serum concentration of Vilazodone can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Vilazodone can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Vilazodone can be decreased when it is combined with Rifapentine.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Vilazodone.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Vilazodone.
RitonavirThe serum concentration of Vilazodone can be increased when it is combined with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Vilazodone.
RolapitantThe metabolism of Vilazodone can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Vilazodone.
RopiniroleThe metabolism of Vilazodone can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Vilazodone.
RosiglitazoneVilazodone may increase the hypoglycemic activities of Rosiglitazone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Vilazodone.
SafrazineSafrazine may increase the serotonergic activities of Vilazodone.
SaquinavirThe serum concentration of Vilazodone can be increased when it is combined with Saquinavir.
SaxagliptinVilazodone may increase the hypoglycemic activities of Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vilazodone.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Vilazodone.
SelegilineSelegiline may increase the serotonergic activities of Vilazodone.
SelegilineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Selegiline.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Vilazodone.
SertralineVilazodone may increase the serotonergic activities of Sertraline.
SertralineThe metabolism of Vilazodone can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Vilazodone.
SildenafilThe serum concentration of Vilazodone can be increased when it is combined with Sildenafil.
SiltuximabThe serum concentration of Vilazodone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Vilazodone can be increased when it is combined with Simeprevir.
SitagliptinVilazodone may increase the hypoglycemic activities of Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Vilazodone.
SotalolThe serum concentration of Sotalol can be increased when it is combined with Vilazodone.
St. John's WortThe serum concentration of Vilazodone can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Vilazodone.
SufentanilSufentanil may increase the serotonergic activities of Vilazodone.
SulfadiazineVilazodone may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleVilazodone may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleThe serum concentration of Vilazodone can be increased when it is combined with Sulfisoxazole.
SulfisoxazoleVilazodone may increase the hypoglycemic activities of Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Vilazodone.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Vilazodone.
SunitinibVilazodone may increase the hypoglycemic activities of Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Vilazodone.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Vilazodone.
TapentadolTapentadol may increase the serotonergic activities of Vilazodone.
TapentadolThe risk or severity of adverse effects can be increased when Vilazodone is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Vilazodone.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Vilazodone.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Vilazodone is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Vilazodone can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Vilazodone can be increased when it is combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Vilazodone.
TerbinafineThe metabolism of Vilazodone can be decreased when combined with Terbinafine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Vilazodone.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Vilazodone.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Vilazodone.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Vilazodone.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Vilazodone.
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Vilazodone.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Vilazodone.
ThioproperazineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Thioproperazine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Vilazodone.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Vilazodone.
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Vilazodone.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Vilazodone.
TiclopidineThe serum concentration of Vilazodone can be increased when it is combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Vilazodone.
TimololThe serum concentration of Timolol can be increased when it is combined with Vilazodone.
TipranavirThe metabolism of Vilazodone can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Vilazodone.
TocilizumabThe serum concentration of Vilazodone can be decreased when it is combined with Tocilizumab.
TolazamideVilazodone may increase the hypoglycemic activities of Tolazamide.
TolbutamideVilazodone may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Vilazodone.
ToloxatoneToloxatone may increase the serotonergic activities of Vilazodone.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Vilazodone.
TramadolVilazodone may increase the neuroexcitatory activities of Tramadol.
TramadolTramadol may increase the serotonergic activities of Vilazodone.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Vilazodone.
TranylcypromineTranylcypromine may increase the serotonergic activities of Vilazodone.
TranylcypromineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Vilazodone.
TrazodoneVilazodone may increase the serotonergic activities of Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Vilazodone.
TrichlormethiazideVilazodone may increase the hyponatremic activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Vilazodone.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Vilazodone.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Vilazodone.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Vilazodone.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Vilazodone.
VenlafaxineThe serum concentration of Vilazodone can be increased when it is combined with Venlafaxine.
VenlafaxineThe risk or severity of adverse effects can be increased when Vilazodone is combined with Venlafaxine.
VerapamilThe serum concentration of Vilazodone can be increased when it is combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Vilazodone.
VoriconazoleThe serum concentration of Vilazodone can be increased when it is combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Vilazodone.
VortioxetineVilazodone may increase the serotonergic activities of Vortioxetine.
WarfarinVilazodone may increase the anticoagulant activities of Warfarin.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Vilazodone.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Vilazodone.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Vilazodone.
ZimelidineZimelidine may increase the serotonergic activities of Vilazodone.
ZiprasidoneThe serum concentration of Vilazodone can be increased when it is combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Vilazodone.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Vilazodone.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Vilazodone.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Vilazodone.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Vilazodone.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Vilazodone.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Vilazodone.
Food Interactions
  • Caution taking vilazodone with foods/herbal product with antiplatelet/anticoagulant properties
  • Gingko bilboa, ginger, garlic, green tea, licorice, horseradish

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Page ME, Cryan JF, Sullivan A, Dalvi A, Saucy B, Manning DR, Lucki I: Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist. J Pharmacol Exp Ther. 2002 Sep;302(3):1220-7. [PubMed:12183683 ]
  2. Adamec R, Bartoszyk GD, Burton P: Effects of systemic injections of vilazodone, a selective serotonin reuptake inhibitor and serotonin 1A receptor agonist, on anxiety induced by predator stress in rats. Eur J Pharmacol. 2004 Nov 3;504(1-2):65-77. [PubMed:15507223 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Link [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Link [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Link [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Page ME, Cryan JF, Sullivan A, Dalvi A, Saucy B, Manning DR, Lucki I: Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist. J Pharmacol Exp Ther. 2002 Sep;302(3):1220-7. [PubMed:12183683 ]
  2. Adamec R, Bartoszyk GD, Burton P: Effects of systemic injections of vilazodone, a selective serotonin reuptake inhibitor and serotonin 1A receptor agonist, on anxiety induced by predator stress in rats. Eur J Pharmacol. 2004 Nov 3;504(1-2):65-77. [PubMed:15507223 ]
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:49 / Updated on September 27, 2016 02:27